Halozyme Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
Thank you, everybody, for joining us again this afternoon at the JMP Securities Life Science Conference. Really excited to be joined next by Halozyme Therapeutics' CEO, Helen Torley. Halozyme obviously is a company we've covered for a long number of years. So, it's been a really great transformation over the last several years. You focused fully on building out the -- focused on the royalty streams and then building upon that with the Antares acquisition.
So, Helen, with that I would just say thank you again for being here and we'll maybe just start with the 30-second high-level overview.
Yeah. For those who are not familiar with Halozyme, we're a profitable biotech company. We have two drug delivery platforms that Jason was referring to: our ENHANZE platform that we license to leading companies to transform their IV drugs into subcu and we also, with the acquisition of Antares, acquired an auto-injector platform.
In addition, the third
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
